Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol for prevention of 5-fluorouracil-related cardiotoxicity in gastrointestinal cancer
IRCT20200907048646N1Phase 3Completed
- Sponsor
- Ardabil University of Medical Sciences
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of carvedilol in gastrointestinal cancer (2 arms), sponsored by Ardabil University of Medical Sciences. Primary endpoints: Cardiotoxicity occurrence during or after chemotherapy, Electrocardiogram changes and 2 more. Started Sep 2020; status: completed.
02
Drugs
carvedilol
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on IRCT20200907048646N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200907048646N1.